baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC DIS.CERT. 03/25 BAYN/ DE000HD3X2M4 /

24/01/2025 21:47:01	Chg.-0.070	Bid21:59:16	Ask21:59:16	Underlying	Strike price	Expiration date	Option type
19.080EUR	-0.37%	19.060 Bid Size: 10,000	19.080 Ask Size: 10,000	BAYER AG NA O.N.	- EUR	28/03/2025	Call

TeleTrader 12/11/2024 Bayer dips 12%, hits 20-year low after earnings report

TeleTrader 12/11/2024 Bayer's sales in Q3 down 3.6% to €9.9 billion

TeleTrader 16/08/2024 Bayer jumps 10% after Roundup court win

GlobeNewswire 02/08/2024 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...

GlobeNewswire 11/07/2024 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...

GlobeNewswire 25/06/2024 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial

GlobeNewswire 30/05/2024 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines

GlobeNewswire 30/05/2024 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...

GlobeNewswire 29/05/2024 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 28/05/2024 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement

TeleTrader 14/05/2024 Bayer's sales in Q1 at €13.7 billion, down 4.3%

GlobeNewswire 02/05/2024 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...

GlobeNewswire 18/04/2024 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...

GlobeNewswire 16/04/2024 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...

GlobeNewswire 11/04/2024 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...

GlobeNewswire 09/04/2024 AskBio Names Mansuo Shannon Chief Scientific Officer

GlobeNewswire 25/03/2024 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...

GlobeNewswire 14/03/2024 Bayer and Aignostics to collaborate on next generation precision oncology

GlobeNewswire 06/03/2024 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...

TeleTrader 05/03/2024 Bayer's Q4 sales at €11.9 billion

GlobeNewswire 04/03/2024 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

TeleTrader 04/03/2024 Earnings preview: Bayer, Broadcom among those in calendar

GlobeNewswire 15/02/2024 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust

GlobeNewswire 13/02/2024 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...

GlobeNewswire 13/02/2024 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure

UC DIS.CERT. 03/25 BAYN/ DE000HD3X2M4 /

If you wish to receive reply to your feedback, please provide your email address.